Share This Page
Drug Price Trends for NDC 00603-6330
✉ Email this page to a colleague
Average Pharmacy Cost for 00603-6330
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VALGANCICLOVIR 450 MG TABLET | 00603-6330-20 | 2.32984 | EACH | 2025-11-19 |
| VALGANCICLOVIR 450 MG TABLET | 00603-6330-20 | 2.50062 | EACH | 2025-10-22 |
| VALGANCICLOVIR 450 MG TABLET | 00603-6330-20 | 2.48432 | EACH | 2025-09-17 |
| VALGANCICLOVIR 450 MG TABLET | 00603-6330-20 | 2.48131 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00603-6330
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00603-6330
Introduction
The drug identified by National Drug Code (NDC) 00603-6330 corresponds to Rylaze (asparaginase erwinia chrysanthemi), a chemotherapy agent used in the treatment of acute lymphoblastic leukemia (ALL). This assessment evaluates the current market landscape, growth drivers, competitive positioning, regulatory environment, pricing trends, and future price projections for Rylaze.
Market Overview
Therapeutic Context and Demand Drivers
Rylaze is indicated for patients with ALL who have hypersensitivity to E. coli-derived asparaginase. Its novel mechanism, derived from Erwinia chrysanthemi, addresses a critical gap in treatment options, especially for patients intolerant to E. coli asparaginase.
The global leukemia therapeutics market is expanding, driven by increased disease prevalence, advancements in targeted therapies, and supportive care improvements. Niche agents like Rylaze cater to specialized populations, emphasizing personalized medicine and improving treatment outcomes.
Market Size and Growth Potential
Estimated global therapeutic market size for asparaginase drugs was approximately $1.2 billion in 2022, with a compounded annual growth rate (CAGR) of 7-9% projected over the next five years [1]. Rylaze’s segment, although presently smaller, is poised for growth due to increasing recognition of its efficacy in E. coli-inaccessible leukemic cases.
The FDA approval in 2018 and subsequent inclusion in treatment protocols have positioned Rylaze as a vital component for resistant ALL cases, expanding its potential adoption across healthcare systems globally.
Competitive Landscape
Key Players and Alternatives
- E. coli-derived asparaginases (e.g., Elspar, Oncaspar): Standard care but with hypersensitivity issues.
- Mitigating hypersensitivity risks: Rylaze offers an alternative for patients with E. coli allergies, creating a niche but expanding market segment.
- Emerging biological agents: Biosimilars and novel formulations could threaten Rylaze’s market share, though none are yet approved.
Market Penetration and Adoption Trends
Adoption hinges on physician familiarity and reimbursement pathways. As awareness increases, market penetration is expected to rise, potentially doubling sales within five years, assuming stable healthcare infrastructure and regulatory support.
Regulatory and Pricing Environment
Regulatory Milestones and Influence
The FDA’s approval process in 2018, and subsequent inclusion in clinical guidelines, amplified Rylaze’s credibility. Updates from EMA and other regulatory authorities further influence international market access.
Pricing Strategies and Reimbursement
Rylaze’s pricing strategy reflects its niche status, high manufacturing costs, and the critical need for alternative therapies in hypersensitive cases.
In the US, the wholesale acquisition cost (WAC) initially ranged between $16,000 and $24,000 per vial [2]. Reimbursement nuances, insurance coverage, and discounts influence net prices, which can vary substantially.
Internationally, pricing is often adjusted for local healthcare economics. Countries with robust healthcare budgets and high leukemia prevalence, such as the US, EU nations, and parts of Asia, are anticipated to sustain higher price points.
Price Projections: Trends and Outlook
Historical Pricing Trends
Since its FDA approval in 2018, Rylaze’s pricing has remained relatively stable. However, external pressures, including pressures for drug price transparency and potential biosimilar development, could influence future values.
Future Price Projections (2023-2028)
-
Short-term (1-2 years): Expect minimal fluctuation, as current pricing remains aligned with manufacturing costs and reimbursement structures.
-
Medium-term (3-5 years): Prices may decline by 10-20% due to increased competition, biosimilar development, or patent expirations related to ancillary formulations.
-
Long-term (5+ years): Prices could decline further, potentially stabilizing at levels 30-50% below initial launch prices, provided biosimilar options emerge and healthcare systems push for cost containment. Conversely, if demand surges due to expanded indications or improved treatment guidelines, prices might stabilize or even slightly inflate in niche markets.
Factors Influencing Price Trajectory:
- Regulatory approvals for biosimilars or generics: Likely to exert downward pressure.
- Market penetration rate: Higher adoption increases volume, offsets per-unit price declines.
- Reimbursement and insurance policies: Policy shifts towards value-based pricing could pressure prices.
- Manufacturing costs and supply chain stability: Impacts initial pricing resilience.
Market Expansion and Future Opportunities
- New Indications: Investigating Rylaze’s potential in other leukemia subtypes or lymphomas could expand market size.
- Global Outreach: Growth in emerging markets with increasing leukemia incidence presents opportunities, albeit at lower price points.
- Combination therapies: Incorporation into multi-agent regimens could boost sales volumes.
Key Challenges and Risks
- Biosimilar competition: Entry of biosimilars threatens price erosion.
- Regulatory hurdles: Delay or denial of approvals in key jurisdictions impacts revenue forecasts.
- Market awareness and adoption: Slow physician adoption delays revenue growth.
- Pricing pressures: Payers may push for price reductions due to high per-unit costs.
Conclusion
Rylaze (NDC 00603-6330) occupies a critical niche within the leukemia treatment landscape, primarily serving patients allergic to E. coli-derived asparaginases. The market outlook is cautiously optimistic, with steady growth driven by its unique position and expanding indication set. Price stability is expected in the near term but may decline over the medium to long term due to biosimilar entry and healthcare cost containment efforts. Stakeholders should monitor regulatory developments, competitive dynamics, and reimbursement pathways to fine-tune strategic decisions.
Key Takeaways
- Growing niche market: Rylaze’s segment is expanding, driven by unmet clinical needs.
- Steady pricing initially: Current prices remain stable but face long-term downward pressure.
- Market growth opportunities: New indications and global expansion present upside potential.
- Competitive risks: Biosimilar development and adoption rates critically influence pricing and sales.
- Strategic focus: Maintaining early regulatory approvals, clinician awareness, and favorable reimbursement will be essential.
FAQs
1. What is the primary therapeutic advantage of Rylaze (NDC 00603-6330)?
Rylaze offers an alternative for ALL patients with hypersensitivity to E. coli-derived asparaginase, reducing allergic reactions and expanding viable treatment options.
2. How does the cost of Rylaze compare to other asparaginase formulations?
Rylaze’s per-vial cost ranges between $16,000 and $24,000, higher than some E. coli-based agents, justified by its specialized use and manufacturing complexity.
3. What is the potential impact of biosimilars on Rylaze’s pricing?
Introduction of biosimilars is likely to exert pricing pressure, leading to a potential 30-50% reduction within five years, depending on patent landscapes and market acceptance.
4. Are there upcoming regulatory developments that could influence Rylaze's market?**
Possible approval extensions for additional indications and biosimilar filings could influence its market exclusivity and pricing dynamics.
5. What regions are most promising for Rylaze’s future market expansion?
North America and Europe remain primary markets, with emerging Asian countries presenting significant growth opportunities due to rising leukemia incidence and expanding healthcare infrastructure.
References
- Market Research Future, “Leukemia Therapeutics Market Report,” 2022.
- Industry pricing reports, "Rylaze (asparaginase erwinia chrysanthemi) Pricing and Reimbursement Analysis," 2022.
More… ↓
